Pantium (Pantoprazole Sodium Sesquihydrate)

Pantoprazole, the active ingredient in Pantium, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is indicated for conditions such as gastro‑oesophageal reflux disease, erosive esophagitis and peptic ulcer disease in adult patients.

GNH USA supplies Pantium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantium is a proton pump inhibitor used to manage acid‑related disorders of the upper gastrointestinal tract.

- Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and regurgitation by decreasing gastric acidity. - Erosive esophagitis: promotes healing of inflamed esophageal tissue caused by acid exposure. - Peptic ulcer disease: supports ulcer resolution and prevents recurrence through sustained acid suppression.

Adverse reactions may occur with pantoprazole therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: loose stools occurring during treatment. - Nausea: occasional feeling of stomach upset. - Abdominal pain: mild discomfort in the upper abdomen.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent diarrhoea with abdominal cramping. - Low magnesium levels: muscle cramps, irregular heartbeat, or seizures in prolonged use.

Before initiating Pantium, consider the following safety measures.

- Assess renal function: adjust use in patients with severe impairment. - Evaluate hepatic status: monitor in moderate liver disease. - Review concomitant medications: avoid drugs that require gastric acidity for absorption. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. - Store at ambient temperature: keep below 25 °C, retain in the original container, and protect from moisture.

Pantoprazole may alter the pharmacokinetics of several co‑administered agents.

Major Interactions (Avoid): - Ketoconazole or itraconazole: reduced antifungal absorption leading to therapeutic failure. - Atazanavir: markedly decreased antiviral exposure, compromising HIV treatment.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Methotrexate (high dose): enhanced toxicity risk; consider dose adjustment or alternative therapy.